Studies in Europe on parenteral use of aminopyrine necessitated the development of a solvent, and a pyrazol synthetic derivative, phenylbutazone (butazolidin®), was developed for this purpose. The aminopyrine and phenylbutazone combination (igrapyrin®) was studied in Europe for its anti-inflammatory and antipyretic effect in rheumatic conditions. The reports1 were enthusiastic, and the drug was introduced in the United States for evaluation.
Because of the occasional serious hazards of aminopyrine therapy and because some of the clinical results obtained with the combination of aminopyrine and phenylbutazone were superior to those obtained with aminopyrine alone, it was decided to investigate the effect of the solvent, phenylbutazone, in the rheumatic diseases. Two recent clinical studies have been reported.2
Selection of Patients.
—Of the 188 patients studied, 115 had peripheral rheumatoid arthritis, 32 had rheumatoid spondylitis, and 41 had miscellaneous diseases.Phenylbutazone alone was given to 107 of the 147
Stephens CAL, Yeoman EE, Holbrook WP, Hill DF, Goodin WL. BENEFITS AND TOXICITY OF PHENYLBUTAZONE (BUTAZOLIDIN®) IN RHEUMATOID ARTHRITIS. JAMA. 1952;150(11):1084–1086. doi:10.1001/jama.1952.03680110024007
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: